1 |
Analysis of human cytomegalovirus susceptibility to novel antiviral agentsJun, Min, Medical Sciences, Faculty of Medicine, UNSW January 2008 (has links)
Human cytomegalovirus (CMV) is a significant infectious agent causing disease in immunocompromised HIV-infected patients, transplant recipients, and neonates. The current antiviral therapeutic strategy against CMV is limited in its utility due to the inherent toxicity and lack of bioavailability of currently available anti-CMV agents, ganciclovir (GCV), cidofovir (CDV), and foscarnet (FOS). The development of the prodrug of GCV, valganciclovir (val-GCV), has vastly improved the bioavailability profile of GCV. However, val-GCV demonstrates limited effectiveness against tissue-invasive CMV diseases as side effects involved with traditional intravenously administered GCV such as haematologic and reproductive toxicities remain. In addition, the emergence of antiviral resistant CMV mutant strains due to prolonged treatment with currently available antivirals necessitates the development of novel anti-CMV agents with reduced toxicity and improved bioavailability. In this study, select groups of novel compounds were analysed for their potential for further development as anti-CMV agents. Three groups of compounds were identified based on two screening methods which included the computer simulated screening process of compounds known as in silico screening and the traditional method of random screening. The first group of compounds (CATi) were identified by in silico screening against the CMV DNA polymerase catalytic aspartate triad, resulting in the identification of 31 compounds with the potential for inhibitory activity against CMV. The second group of compounds (PRO-i) were identified through in silico screening against the CMV protease, identifying a total of 18 lead compounds exhibiting structural complementarity with CMV protease. The third and final group of compounds (TPEX) were identified through random screening and consisted of plant extracts purified from tropical plants. All three compounds were initially screened for cytotoxicity against human fibroblasts. Plaque reduction assays were performed using compounds with acceptable levels of cytotoxicity to determine the ability of the compounds to inhibit the replication of the laboratory antiviral sensitive CMV strain, Towne. Two of the PRO-i compounds demonstrated good antiviral activity against CMV. Eleven percent (2/18) of the PRO-i compounds inhibited CMV replication, with PRO-i-43 and PRO-i??-44 displaying mean 50% inhibitory concentrations (IC50) of 4.8 ?? 1.2 ??M and 8.04 ??M, respectively. PRO-i-43 and PRO-i-44 are thus good candidates for further development as novel antiviral agents against CMV. The majority of CATi and TPEX compounds displayed significant cytotoxicity against human fibroblasts and compounds with acceptable levels of cytotoxicities did not significantly inhibit CMV replication. However, the identification of compounds with low cytotoxicities provides a good foundation for further development of novel anti-CMV agents with superior antiviral activity. In silico screening against three-dimensional viral protein models is a useful strategy for the identification of novel antiviral agents with the potential for inhibitory activity against CMV. Structural modification to produce potent derivatives of the identified anti-CMV compounds (PRO-i-43 and PRO-i-44) is a good option for the further development of novel antiviral agents against CMV. Such further examination of the identified compounds with anti-CMV activity is required to investigate their activity against not only antiviral sensitive CMV strains but also resistant CMV strains. Further investigations will yield new insights into their target, allowing further identification of compounds with potential anti-CMV activity with pharmaceutical application.
|
2 |
Analysis of human cytomegalovirus susceptibility to novel antiviral agentsJun, Min, Medical Sciences, Faculty of Medicine, UNSW January 2008 (has links)
Human cytomegalovirus (CMV) is a significant infectious agent causing disease in immunocompromised HIV-infected patients, transplant recipients, and neonates. The current antiviral therapeutic strategy against CMV is limited in its utility due to the inherent toxicity and lack of bioavailability of currently available anti-CMV agents, ganciclovir (GCV), cidofovir (CDV), and foscarnet (FOS). The development of the prodrug of GCV, valganciclovir (val-GCV), has vastly improved the bioavailability profile of GCV. However, val-GCV demonstrates limited effectiveness against tissue-invasive CMV diseases as side effects involved with traditional intravenously administered GCV such as haematologic and reproductive toxicities remain. In addition, the emergence of antiviral resistant CMV mutant strains due to prolonged treatment with currently available antivirals necessitates the development of novel anti-CMV agents with reduced toxicity and improved bioavailability. In this study, select groups of novel compounds were analysed for their potential for further development as anti-CMV agents. Three groups of compounds were identified based on two screening methods which included the computer simulated screening process of compounds known as in silico screening and the traditional method of random screening. The first group of compounds (CATi) were identified by in silico screening against the CMV DNA polymerase catalytic aspartate triad, resulting in the identification of 31 compounds with the potential for inhibitory activity against CMV. The second group of compounds (PRO-i) were identified through in silico screening against the CMV protease, identifying a total of 18 lead compounds exhibiting structural complementarity with CMV protease. The third and final group of compounds (TPEX) were identified through random screening and consisted of plant extracts purified from tropical plants. All three compounds were initially screened for cytotoxicity against human fibroblasts. Plaque reduction assays were performed using compounds with acceptable levels of cytotoxicity to determine the ability of the compounds to inhibit the replication of the laboratory antiviral sensitive CMV strain, Towne. Two of the PRO-i compounds demonstrated good antiviral activity against CMV. Eleven percent (2/18) of the PRO-i compounds inhibited CMV replication, with PRO-i-43 and PRO-i??-44 displaying mean 50% inhibitory concentrations (IC50) of 4.8 ?? 1.2 ??M and 8.04 ??M, respectively. PRO-i-43 and PRO-i-44 are thus good candidates for further development as novel antiviral agents against CMV. The majority of CATi and TPEX compounds displayed significant cytotoxicity against human fibroblasts and compounds with acceptable levels of cytotoxicities did not significantly inhibit CMV replication. However, the identification of compounds with low cytotoxicities provides a good foundation for further development of novel anti-CMV agents with superior antiviral activity. In silico screening against three-dimensional viral protein models is a useful strategy for the identification of novel antiviral agents with the potential for inhibitory activity against CMV. Structural modification to produce potent derivatives of the identified anti-CMV compounds (PRO-i-43 and PRO-i-44) is a good option for the further development of novel antiviral agents against CMV. Such further examination of the identified compounds with anti-CMV activity is required to investigate their activity against not only antiviral sensitive CMV strains but also resistant CMV strains. Further investigations will yield new insights into their target, allowing further identification of compounds with potential anti-CMV activity with pharmaceutical application.
|
3 |
Combined virtual/experimental multicomponent solid forms screening of sildenafil: new salts, cocrystals, and hybrid salt-cocrystalsBarbas, R., Font-Bardia, M., Paradkar, Anant R, Hunter, C.A., Prohens, R. 30 October 2018 (has links)
Yes / New multicomponent solid forms of sildenafil have been discovered
by means of a combined virtual/experimental cocrystal screening. Coformer
selection of candidates was conducted based on an in silico screening method from
a database of more than 2000 organic compounds, and the intensive experimental
screen produced 23 new solid forms. Since the 12 coformers chosen have a
combination of phenol and carboxylic acid groups, a variety of cocrystals, salts, and
hybrid salt-cocrystals were discovered and characterized.
|
4 |
In silico und in vitro Screening von Proteinliganden zur ApoptoseinduktionFüllbeck, Melanie 10 December 2007 (has links)
Die moderne Tumormedizin hat das Ziel die deregulierte Wachstumskontrolle und die Überlebensstrategien maligner Tumoren zu überwinden. Mittels computerbasierter Methoden sollten hierzu in dieser Arbeit neue apoptoseinduzierende Substanzen gefunden und deren Wirksamkeit in späteren in vitro Experimenten überprüft werden. In drei Modellprojekten konnten neue Substanzen identifiziert werden, die Apoptose in Tumorzellen induzieren. Im ersten Projekt wurden Inhibitoren der an das COP9 Signalosom (CSN-) assoziierten Kinasen CK2 und PKD mittels der Leitstrukturen Curcumin und Emodin gefunden. Im zweiten Projekt wurde der Naturstoff Betulinsäure (betulinic acid, BA) bezüglich seines Wirkmechanismus untersucht. Die Ergebnisse haben gezeigt, dass die BA-induzierte Apoptose weitestgehend unabhängig von den pro- und anti-apoptotischen Proteinen der Bcl-2-Familie, aber in Abhängigkeit von aktiven Caspasen, ausgelöst wird. Durch ein in silico Screening und die Verwendung eines neuen Eigenschaftsfilters konnten neuen BA-Analoga identifiziert werden. Zur Bewertung der Ergebnisse des in silico Screenings wurden Daten des National Cancer Institutes (NCI) verwendet. Im dritten Projekt wurden mittels in silico Screening, Docking-Experimenten und in vitro Screenings zwei neue Bcl-2-Inhibitoren identifiziert, die derzeit in funktionellen Experimenten getestet werden. Durch den Einbau eines niedermolekularen, photoschaltbaren Moleküls an die Aminosäuren-Seitenketten des alpha-helikalen Peptides aus der BH3-Domäne von Bid konnte eine gezielte Aktivierung und damit auch eine gezielte Apoptoseinduktion in Tumorzellen ausgelöst werden. Die Methode des in silico Screenings hat gezeigt, dass die Zeit und Kosten für die Suche nach Wirkstoffen reduziert werden können. Die gefundenen Treffer können als neue Leitstrukturen für weitere in silico Screenings ihre Verwendung finden oder mit Hilfe von Optimierungsprozessen in weitere Stufen der Entwicklung eintreten. / Nowadays, cancer research is focused on the overcoming of survival strategies of malign tumors. In the present work, computer-based methods lead to the identification of novel apoptosis inducing molecules, whose potency should be validated in in vitro experiments. Novel compounds, which induce apoptosis in cancer cells, could be identified on the basis of three projects. Inhibitors for the COP9 signalosome (CSN) associated kinases CK2 and PKD could be discovered using curcumin and emodin as lead compounds. Investigations concerning the mechanism-of-action of betulinic acid (BA) should give information about the function of the Bcl-2 protein family in the BA induced cell death. The experiments, which are focused on the mitochondrial signalling pathway, revealed that BA induces apoptosis in an almost independent manner with regards to the pro- and anti-apoptotic Bcl-2 proteins, but dependent on the presence of activated caspases. Via an in silico screening and the utilisation of a new property filter, novel BA analogues could be identified. For the first time, the data of the National Cancer Institute (NCI) is employed to evaluate results from the in silico screening. In the third project two novel Bcl-2 inhibitors have been identified via in silico screenings, docking experiments and in vitro screenings, which are performed at the moment. The insertion of a photo-switchable compound to the amino acid side chain of an alpha-helical peptide from the pro-apoptotic protein Bid triggered the effect of a modulator, which results in a controllable activation and initiation of apoptosis in tumor cells. In silico screenings as a reliable method corroborated that a systematical evaluation of the virtual hits could decrease the time and costs of experimental testings. The identified hits could serve as novel lead compounds for further in silico screenings or enter the next steps in the development of novel drugs using optimisation methods.
|
5 |
Conception, synthèse et dévelopement d'inhibiteurs du répresseur transcriptionnel mycobactérien ETHR selon une approche par fragments. Une nouvelle approche dans la lutte contre la tuberculose / Use of fragment-based approaches for the design, synthesis and development of new ethr inhibitors as a new strategy to fight tuberculosisVillemagne, Baptiste 28 September 2012 (has links)
Avec plus d’un million et demi de morts chaque année, la tuberculose reste aujourd’hui la seconde cause de mortalité liée à un agent infectieux. De plus l’organisation mondiale de la santé (OMS) a estimé en 2011 qu’un tiers de la population mondiale était porteuse du bacille Mycobacterium tuberculosis responsable de la maladie. Depuis la fin des années 1980, une recrudescence du nombre de cas de tuberculose est observée à l’échelle mondiale. Cette recrudescence est due à la fois à l’apparition de souches résistantes, mais également à l’épidémie de VIH qui est un facteur de prédisposition au déclenchement de la maladie.En 2000, le répresseur transcriptionnel mycobactérien EthR a été identifié comme étant un régulateur clé dans la bioactivation de l’éthionamide (ETH), un antituberculeux utilisé pour le traitement de seconde intention. En 2009, l’inhibition de ce répresseur par le développement de molécules « drug-like » a permis de potentialiser l’activité de l’éthionamide d’un facteur 3 chez la souris infectée et a permis de valider cette cible pour une future approche thérapeutique.Ce travail repose sur la découverte et l’optimisation de nouveaux inhibiteurs de ce répresseur transcriptionnel mycobactérien, à partir d’une petite molécule appelée « fragment » qui a été cocristallisée avec la protéine. Par la combinaison d’un criblage in silico, d’un criblage in vitro des touches identifiées, de l’étude des structures radiocristallographiques des complexes ligands/protéines et de la chimie médicinale, le développement de trois approches complémentaires dites « fragmentgrowing », « fragment-merging » et « fragment-linking » a permis de développer des composés présentant de fortes activités. Ces résultats permettront très prochainement de sélectionner une nouvelle molécule issue de ce travail dans la perspective de nouveaux essais sur le modèle murin. / Tuberculosis (TB) remains the leading cause of death due to a single infective agent with more than 1.5 million people killed each year. In 2011, the world health organization (WHO) estimated that one third of the world’s population is infected with Mycobacterium tuberculosis, the pathogen responsible for the disease. This phenomenon may be due to an explosive escalation of TB incidence that occurred in the 1980s due to the emergence of both resistant strains and HIV epidemic.In 2000, EthR, a mycobacterial transcriptional repressor, was identified as a key modulator of ethionamide (ETH) bioactivation. ETH is one of the main second-line drugs used to treat drug resistant strains. In 2009, it was shown that co-administration of ETH and drug-like inhibitors of EthR was able to boost ETH activity threefold in a mouse-model of TB-infection, thus validating the target for a new therapeutic strategy.This work deals with the discovery and optimisation of new EthR inhibitors, based on a small molecule, called a “fragment”, co-crystallized with the protein. We combined in silico screening, in vitro evaluation of the hit compounds, study of co-crystal structures and medicinal chemistry to develop three complementary approaches called “fragment growing”, “fragment merging” and “fragment linking” that led to the discovery of very potent inhibitors. Based on these results, we are currently selecting a potential candidate for new in vivo experiments.
|
6 |
Contribution à l'étude chimique et pharmacochimique de dérivés mono- bi- et tricycliques de pyridazines / Contribution to the chemical and pharmacological study of mono- bi- and tricyclic pyridazine derivativesBlaise, Emilie 26 September 2014 (has links)
La protéine kinase DYRK1A fait partie du groupe des CMGC kinases et est impliquée dans divers processus neurodégénératifs tels que la maladie d’Alzheimer.Dans ce cadre, une étude topologique a été menée autour d’un hit imidazo[1,2-B]pyridazine identifié par un criblage biologique. Ce composé a servi à concevoir des inhibiteurs ATP-Compétitifs de DYRK1A par l’utilisation de méthodes métallo-Catalysées (Pd, Cu) pour introduire divers fragments fonctionnalisés.Sur les soixante dérivés imidazo[1,2-X]azine synthétisés, sept composés ont montré une affinité nanomolaire pour DYRK1A (IC50 = 41-130 nM). En parallèle de ce travail de pharmacochimie, le développement de nouvelles méthodologies de synthèse a visé à la polysubstitution régiosélective du cycle pyridazine.En dernier lieu, nous avons donné les éléments et concepts permettant la construction de chimiothèques virtuelles dérivées de pyridazines et destinées à être criblées in silico. / DYRK1A protein kinase belongs to the CMGC group and is involved in neurodegenerative disorders such as Alzheimer’s disease.In this context we examined an imidazo[1,2-B]pyridazine hit identified by biological screening, through detailed structure-Activity relationship studies. This compound was used to synthesize DYRK1A ATP-Competitive inhibitors by using metallo-Catalyzed methodologies (Pd, Cu) in order to introduce various functionalized moieties.Out of the 60 derivatives synthesized, 7 compounds showed nanomolar activities (IC50 = 41-130 nM).Beside this work of medicinal chemistry, new synthetic methodologies has been developed to regioselectively access polysubstituted pyridazine derivatives. Finally, we developed data and concepts to establish virtual pyridazine libraries for in silico screening.
|
Page generated in 0.5761 seconds